☰

Don L. Gibbons, Ph.D. - Publications

Affiliations: 
2004 Yeshiva University, New York, NY, United States 
Area:
Molecular Biology, Microbiology Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

236 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, ... ... Gibbons DL, et al. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal For Immunotherapy of Cancer. 12. PMID 39448200 DOI: 10.1136/jitc-2024-009677  0.328
2024 Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A, ... ... Gibbons DL, et al. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 39150543 DOI: 10.1158/1078-0432.CCR-24-0361  0.37
2024 Miao S, Rodriguez BL, Gibbons DL. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors. Cancers. 16. PMID 39061147 DOI: 10.3390/cancers16142507  0.391
2024 Konen JM, Wu H, Gibbons DL. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities. Trends in Pharmacological Sciences. 45: 520-536. PMID 38744552 DOI: 10.1016/j.tips.2024.04.006  0.334
2024 Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, ... ... Gibbons DL, et al. Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors. Molecular Cancer Therapeutics. PMID 38648067 DOI: 10.1158/1535-7163.MCT-23-0866  0.329
2024 Li H, Hu X, Ning MS, Fuller GN, Stewart JM, Gilliam JC, Wu J, Le X, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Futreal A, Zhang J. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Frontiers in Oncology. 14: 1324057. PMID 38590653 DOI: 10.3389/fonc.2024.1324057  0.308
2023 Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, et al. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 38012986 DOI: 10.1016/j.jtho.2023.11.020  0.319
2023 Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, ... ... Gibbons DL, et al. Pathomic Features Reveal Immune and Molecular Evolution from Lung Preneoplasia to Invasive Adenocarcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 100326. PMID 37678674 DOI: 10.1016/j.modpat.2023.100326  0.35
2023 Konen JM, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. The Journal of Clinical Investigation. 133. PMID 37655662 DOI: 10.1172/JCI163128  0.371
2023 Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, ... ... Gibbons DL, et al. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Frontiers in Immunology. 14: 1161869. PMID 37449205 DOI: 10.3389/fimmu.2023.1161869  0.311
2023 Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, ... ... Gibbons DL, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics. PMID 37024582 DOI: 10.1038/s41588-023-01355-5  0.342
2022 Kang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, Young I, Malin CM, Kang Y, Gibbons DL, Sica G, Fu H, Ramalingam SS, Jin L, Kang S. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Reports. 41: 111827. PMID 36516759 DOI: 10.1016/j.celrep.2022.111827  0.326
2022 Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, Wang J, Raso MG, Lu W, Khan K, Solis LS, Batra H, Tang X, Fradette JF, Kundu ST, Gibbons DL. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Reports. 40: 111429. PMID 36170810 DOI: 10.1016/j.celrep.2022.111429  0.346
2022 Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, ... ... Gibbons DL, et al. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer (Amsterdam, Netherlands). 172: 19-28. PMID 35973335 DOI: 10.1016/j.lungcan.2022.08.007  0.325
2022 Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, et al. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. Jama Network Open. 5: e2215589. PMID 35666500 DOI: 10.1001/jamanetworkopen.2022.15589  0.311
2022 Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, ... ... Gibbons DL, et al. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 cytotoxic T-cell response. Genes & Development. PMID 35654454 DOI: 10.1101/gad.349321.121  0.318
2022 Bajaj R, Warner AN, Fradette JF, Gibbons DL. Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis. Cells. 11. PMID 35563790 DOI: 10.3390/cells11091484  0.302
2022 Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, ... ... Gibbons DL, et al. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental & Clinical Cancer Research : Cr. 41: 172. PMID 35546239 DOI: 10.1186/s13046-022-02361-x  0.308
2022 Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, ... ... Gibbons DL, et al. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. PMID 35190177 DOI: 10.1016/j.jtcvs.2022.01.019  0.331
2022 Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, ... ... Gibbons DL, et al. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. Journal For Immunotherapy of Cancer. 10. PMID 35110355 DOI: 10.1136/jitc-2021-003082  0.366
2021 Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, ... ... Gibbons D, et al. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications. 12: 7081. PMID 34873156 DOI: 10.1038/s41467-021-27341-1  0.368
2021 Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, ... ... Gibbons DL, et al. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications. 12: 6655. PMID 34789716 DOI: 10.1038/s41467-021-26821-8  0.36
2021 Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine. PMID 34580079 DOI: 10.1101/cshperspect.a037895  0.332
2021 Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, et al. Poziotinib for Patients With Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101113. PMID 34550757 DOI: 10.1200/JCO.21.01113  0.325
2021 Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, ... Gibbons DL, et al. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. Jco Precision Oncology. 5. PMID 34377884 DOI: 10.1200/PO.20.00532  0.335
2021 Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, ... ... Gibbons DL, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Journal For Immunotherapy of Cancer. 9. PMID 34376553 DOI: 10.1136/jitc-2021-002891  0.383
2021 Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, ... Gibbons DL, et al. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS mutant lung cancer. Jci Insight. PMID 34309585 DOI: 10.1172/jci.insight.148392  0.343
2021 Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, ... ... Gibbons DL, et al. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34274504 DOI: 10.1016/j.jtho.2021.07.002  0.305
2021 Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications. 12: 2606. PMID 33972557 DOI: 10.1038/s41467-021-22875-w  0.32
2021 Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, ... ... Gibbons DL, et al. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Reports. 35: 109009. PMID 33882319 DOI: 10.1016/j.celrep.2021.109009  0.326
2021 Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, ... ... Gibbons DL, et al. Single-Cell Expression Landscape of SARS-CoV-2 Receptor and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers. 13. PMID 33809063 DOI: 10.3390/cancers13061250  0.336
2021 Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Translational Lung Cancer Research. 10: 590-606. PMID 33569339 DOI: 10.21037/tlcr-20-573  0.317
2021 Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC. Cancer Research. PMID 33402388 DOI: 10.1158/0008-5472.CAN-20-1895  0.355
2020 Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, et al. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. American Journal of Cancer Research. 10: 4464-4475. PMID 33415011  0.33
2020 Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, et al. AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors. Molecular Cancer Research : McR. PMID 33172976 DOI: 10.1158/1541-7786.MCR-20-0414  0.31
2020 Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, ... ... Gibbons DL, et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology. 21: 271. PMID 33148332 DOI: 10.1186/s13059-020-02175-0  0.3
2020 Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, ... ... Gibbons DL, et al. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33096269 DOI: 10.1016/j.jtho.2020.09.027  0.37
2020 Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. A pro-tumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. The Journal of Clinical Investigation. PMID 32931483 DOI: 10.1172/Jci137186  0.396
2020 Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, ... Gibbons DL, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 T cell exhaustion. Nature Communications. 11: 4520. PMID 32908154 DOI: 10.1038/S41467-020-18298-8  0.397
2020 Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, ... ... Gibbons DL, et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine. 12. PMID 32878980 DOI: 10.1126/Scitranslmed.Aaz4589  0.351
2020 Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, et al. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer. PMID 32763065 DOI: 10.1016/J.Cllc.2020.06.003  0.364
2020 Bajaj R, Kundu ST, Grzeskowiak CL, Fradette JJ, Scott KL, Creighton CJ, Gibbons DL. IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. Oncogene. PMID 32753652 DOI: 10.1038/S41388-020-01410-Z  0.394
2020 Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, ... ... Gibbons DL, et al. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer (Amsterdam, Netherlands). 146: 303-309. PMID 32619781 DOI: 10.1016/J.Lungcan.2020.06.022  0.398
2020 Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 32442601 DOI: 10.1016/J.Matbio.2020.05.001  0.336
2020 Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, ... ... Gibbons DL, et al. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32389639 DOI: 10.1016/J.Jtho.2020.04.026  0.394
2020 Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, ... ... Gibbons DL, et al. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. Journal For Immunotherapy of Cancer. 8. PMID 32350118 DOI: 10.1136/Jitc-2019-000405  0.446
2020 Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, ... ... Gibbons DL, et al. F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy : Cii. PMID 32300858 DOI: 10.1007/S00262-020-02560-5  0.372
2020 Gaudreau PO, Lee JJ, Heymach JV, Gibbons DL. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clinical Lung Cancer. PMID 32299768 DOI: 10.1016/J.Cllc.2020.02.019  0.381
2020 Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella F, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, ... ... Gibbons DL, et al. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32193228 DOI: 10.1158/1078-0432.Ccr-19-4180  0.369
2020 Tan X, Banerjee P, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, ... ... Gibbons DL, et al. Erratum: PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma (Science Translational Medicine DOI: 10.1016/j.bbcan.2016.06.002) Science Translational Medicine. 12. PMID 32188723 DOI: 10.1126/Scitranslmed.Abb5995  0.317
2020 Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, ... ... Gibbons DL, et al. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32068166 DOI: 10.1016/J.Jtho.2020.01.009  0.415
2020 Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, ... ... Gibbons DL, et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications. 11: 603. PMID 32001676 DOI: 10.1038/S41467-019-14273-0  0.443
2020 Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, ... ... Gibbons DL, et al. PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Science Translational Medicine. 12. PMID 31969487 DOI: 10.1126/Scitranslmed.Aax3772  0.41
2020 Konen J, Rodriguez BL, Gibson L, Minelli R, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Abstract A43: Identifying a role for Ntrk1 in regulating immune functionality and checkpoint blockade resistance in Kras/p53 mutant lung cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-A43  0.493
2020 Padhye A, Rodriguez BL, Fradette JJ, Ungewiss C, Gibbons DL. Abstract B02: Dissecting tumor cell heterogeneity to identify therapeutic vulnerabilities in Kras-mutant lung cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B02  0.475
2020 Arniella M, Ravi A, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, et al. Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative Cancer Research. 80: 5902-5902. DOI: 10.1158/1538-7445.Am2020-5902  0.49
2020 Sinjab A, Han G, Treekitkarnmongkol W, Brennan P, Hara K, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Zhang J, Sepesi B, Cascone T, Gibbons DL, Chen J, Eapen G, et al. Abstract 1518: A single-cell transcriptomic atlas of lung adenocarcinoma and adjacent normal-appearing tissue Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1518  0.381
2019 Creelan BC, Yeh T, Kim SW, Nogami N, Kim DW, Chow LQ, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL. Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii31-ii32. PMID 32131217 DOI: 10.1093/Annonc/Mdz067.001  0.401
2019 Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells. 9. PMID 31878283 DOI: 10.3390/Cells9010052  0.343
2019 Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, et al. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31778797 DOI: 10.1016/J.Jtho.2019.10.024  0.427
2019 Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, Bajaj R, Fradette JJ, Minelli R, Peoples MD, Carugo A, Chen F, Bristow C, Kovacs JJ, Barton MC, ... ... Gibbons DL, et al. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nature Communications. 10: 5125. PMID 31719531 DOI: 10.1038/S41467-019-12832-Z  0.469
2019 Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, et al. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. The Annals of Thoracic Surgery. PMID 31550464 DOI: 10.1016/J.Athoracsur.2019.08.029  0.446
2019 Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra-Cuentas ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31282941 DOI: 10.1093/Annonc/Mdz207  0.449
2019 Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, et al. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers. 11. PMID 31137625 DOI: 10.3390/Cancers11050714  0.449
2019 Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900201. PMID 31067138 DOI: 10.1200/Jco.19.00201  0.389
2019 Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers. 11. PMID 30986992 DOI: 10.3390/Cancers11040462  0.465
2019 Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS, Gibbons DL. A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer. Scientific Reports. 9: 4819. PMID 30894630 DOI: 10.1038/S41598-019-41301-2  0.457
2019 Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, ... ... Gibbons DL, et al. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine. 11. PMID 30867319 DOI: 10.1126/Scitranslmed.Aaq1238  0.477
2019 Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, et al. PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30780001 DOI: 10.1016/J.Jtho.2019.02.008  0.461
2019 Sen T, Rodriguez BL, Chen L, Della Corte C, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, ... ... Gibbons DL, et al. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discovery. PMID 30777870 DOI: 10.1158/2159-8290.Cd-18-1020  0.438
2019 Mitchell KG, Diao L, Tran HT, Negrao MV, Karpinets T, Wang J, Parra Cuentas ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Vaporciyan AA, Swisher S, Cascone T, Wistuba II, ... ... Gibbons DL, et al. Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer. Journal of Clinical Oncology. 37: e14047-e14047. DOI: 10.1200/Jco.2019.37.15_Suppl.E14047  0.368
2019 Hong L, Dibaj S, Negrao MV, Reuben A, Roarty E, Rinsurongkawong W, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Futreal PA, Wistuba II, Roth JA, et al. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 9017-9017. DOI: 10.1200/Jco.2019.37.15_Suppl.9017  0.357
2019 Reuben A, Zhang J, Lin HY, Little L, Gumbs C, Tran HT, Wang L, Haymaker CL, Mehran RJ, Rice DC, Walsh GL, Lee JJ, Wistuba II, Swisher S, Vaporciyan AA, ... ... Gibbons DL, et al. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial). Journal of Clinical Oncology. 37: 8532-8532. DOI: 10.1200/Jco.2019.37.15_Suppl.8532  0.46
2019 Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, Fossella FV, Mott F, Papadimitrakopoulou V, Blumenschein GR, Le X, Federico L, Cuentas ERP, Bernatchez C, Wistuba II, ... ... Gibbons DL, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. Journal of Clinical Oncology. 37: 8504-8504. DOI: 10.1200/Jco.2019.37.15_Suppl.8504  0.414
2019 Sen T, Rodriguez BL, Chen L, Morikawa N, Fujimoto J, Diao L, Fan Y, Wang J, Glisson BS, Wistuba I, Sage J, Heymach JV, Gibbons DL, Byers LA. Abstract A153: Targeting DNA damage response upregulates PD-L1 level and promotes antitumor immunity in small-cell lung cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A153  0.409
2019 Chen L, Diao L, Yi X, Rodriguez BL, Li Y, Villalobos P, Cascone T, Liu X, Tan L, Lorenzi P, Fradette J, Peng D, Skoulidis F, Fan Y, Rodriguez-Canales J, ... ... Gibbons D, et al. Abstract A059: Tackling the tumor microenvironment with CD38 blockade to enhance cancer immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A059  0.42
2019 Negrao MV, Karpinets T, Li J, Reuben A, Haymaker C, Mitchell KG, Fujimoto J, Chow C, Parra ER, Federico L, Zhang J, Vaporciyan AA, Bernatchez C, Cascone T, Sepesi B, ... ... Gibbons DL, et al. Abstract 1176: Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression Cancer Research. 79: 1176-1176. DOI: 10.1158/1538-7445.Sabcs18-1176  0.456
2019 Le X, Negrao MV, Reuben A, Lee W, Parra E, Li J, Karpinets T, Behrens C, Sepesi B, Vaporiciyan A, Roth J, Haymaker C, Roarty E, Zhang J, Bernatchez C, ... ... Gibbons D, et al. Abstract 5028: Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype Cancer Research. 79: 5028-5028. DOI: 10.1158/1538-7445.Am2019-5028  0.473
2019 Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Raja GV, Pena ER, Hollander PD, Bhangre N, Shin C, Martinez M, ... ... Gibbons DL, et al. Abstract 3761: Regulation of metastasis by CD8 T lymphocytes Cancer Research. 79: 3761-3761. DOI: 10.1158/1538-7445.Am2019-3761  0.393
2019 Ramkumar K, Tong P, Fan Y, Peng D, Heymach JV, Gibbons DL, Wang J, Byers LA. Abstract 276: Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress Cancer Research. 79: 276-276. DOI: 10.1158/1538-7445.Am2019-276  0.448
2019 Ramkumar K, Corte CMD, Diao L, Cardnell RJ, Papadimitrakopoulou VA, Heymach JV, Wang J, Gibbons DL, Byers LA. Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B024  0.491
2019 Rocha P, Salazar R, Solorzano J, Zhang J, Mino B, Parra E, Ledesma D, Kadara H, Zhang J, Vaporciyan A, Rice D, Kalhor N, Moran C, Gibbons D, Weissferdt A, et al. P1.04-79 CD73 Expression in Lung Adenocarcinomas and Immunological and Molecular Associations Journal of Thoracic Oncology. 14: S473. DOI: 10.1016/J.Jtho.2019.08.982  0.356
2019 Gaudreau P, Peng D, Rodriguez B, Fradette J, Gibson L, Della Corte C, Sen T, Kundu S, Chen L, Wargo J, Gibbons D. P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC Journal of Thoracic Oncology. 14: S449-S450. DOI: 10.1016/J.Jtho.2019.08.929  0.336
2019 Gaudreau P, Ajami N, Sepesi B, Karpinets T, Reuben A, Wong M, Parra E, Federico L, Gopalakrishnan V, Mitchell K, Negrao M, Spencer C, Vaporciyan A, Weissferdt A, Haymaker C, ... ... Gibbons D, et al. P1.04-11 Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data Journal of Thoracic Oncology. 14: S443. DOI: 10.1016/J.Jtho.2019.08.914  0.33
2019 Kudo Y, Haymaker C, Zhang J, Reuben A, Duose D, Fujimoto J, Roy-Chowdhuri S, Solis L, Dejima H, Cuentas EP, Mino B, Ikeda N, Luthra R, Gibbons D, Zhang J, et al. P1.04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S441. DOI: 10.1016/J.Jtho.2019.08.910  0.434
2019 Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Lanman R, Raymond V, Elamin Y, Altan M, ... ... Gibbons D, et al. P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing Journal of Thoracic Oncology. 14: S399-S400. DOI: 10.1016/J.Jtho.2019.08.813  0.306
2019 Reuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic A, Benzeno S, Vignali M, Wu XX, Ye Y, ... ... Gibbons D, et al. MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S293. DOI: 10.1016/J.Jtho.2019.08.589  0.431
2019 Elamin Y, Robichaux J, Carter B, Altan M, Gibbons D, Fossella F, Simon G, Lam V, Blumenschein G, Tsao A, Kurie J, Mott F, Negrao M, Hu L, He J, et al. MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14: S282-S283. DOI: 10.1016/J.Jtho.2019.08.567  0.449
2019 Negrao M, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg M, Wu C, Zhang J, Barreto D, Rinsurongkawong W, Simon G, ... ... Gibbons D, et al. MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S257-S258. DOI: 10.1016/J.Jtho.2019.08.514  0.44
2019 Chen R, Jin Y, Li J, Zhang J, Fujimoto J, Lee W, Hu X, Chen Y, Behrens C, Chow C, Parra E, Little L, Gumbs C, Song X, Roarty E, ... ... Gibbons D, et al. OA15.04 Genomic and TCR Intratumor Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival Journal of Thoracic Oncology. 14: S246-S247. DOI: 10.1016/J.Jtho.2019.08.491  0.41
2019 Sepesi B, Cascone T, William W, Lin H, Leung C, Weissferdt A, Walsh G, Rice D, Roth J, Mehran R, Hofstetter W, Antonoff M, Fossella F, Mott F, Le X, ... ... Gibbons D, et al. OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study Journal of Thoracic Oncology. 14: S241-S242. DOI: 10.1016/J.Jtho.2019.08.481  0.426
2019 Gaudreau P, Negrao M, Mitchell K, Corsini E, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra E, Li J, Behrens C, Correa A, Gomez D, Vaporciyan A, ... ... Gibbons D, et al. P2.04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC Journal of Thoracic Oncology. 14: S715. DOI: 10.1016/J.Jtho.2019.08.1524  0.326
2018 Cascone T, William WN, Weissferdt A, Leung CH, Federico L, Haymaker C, Bernatchez C, Fossella FV, Mott FE, Papadimitrakopoulou VA, Byers L, Lam VK, Godoy MC, Carter B, Lee JJ, ... ... Gibbons DL, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii738. PMID 32138023 DOI: 10.1093/Annonc/Mdy424.059  0.436
2018 Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Lee JJ, ... ... Gibbons DL, et al. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii680. PMID 32137872 DOI: 10.1093/Annonc/Mdy304.035  0.449
2018 Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL. TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nature Communications. 9: 2731. PMID 30013069 DOI: 10.1038/S41467-018-05013-X  0.458
2018 Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, ... ... Gibbons DL, et al. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nature Communications. 9: 2732. PMID 30013058 DOI: 10.1038/S41467-018-04572-3  0.433
2018 Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette J, ... ... Gibbons DL, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discovery. PMID 30012853 DOI: 10.1158/2159-8290.Cd-17-1033  0.373
2018 Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, ... ... Gibbons DL, et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Journal For Immunotherapy of Cancer. 6: 48. PMID 29871672 DOI: 10.1186/S40425-018-0368-0  0.465
2018 Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, ... Gibbons DL, et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: 1072. PMID 29688333 DOI: 10.1093/Annonc/Mdx062  0.353
2018 Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, et al. Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29526824 DOI: 10.1016/J.Jtho.2018.03.002  0.438
2018 Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. PMID 29510096 DOI: 10.1016/J.Athoracsur.2018.01.081  0.374
2018 Creighton CJ, Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski D, Ittmann M. Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29440175 DOI: 10.1158/1078-0432.Ccr-17-3378  0.365
2018 Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, et al. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. The Journal of Clinical Investigation. PMID 29324442 DOI: 10.1172/Jci97225  0.353
2018 Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The fibrotic tumor stroma. The Journal of Clinical Investigation. 128: 16-25. PMID 29293090 DOI: 10.1172/Jci93554  0.358
2018 Federico L, Haymaker CL, Forget M, Ravelli A, Bhatta A, Karpinets T, Zhang R, Weissferdt A, Fang B, Zhang J, Cascone T, Vaporciyan AA, Futreal A, Wistuba II, Sepesi B, ... ... Gibbons DL, et al. A preclinical study of tumor-infiltrating lymphocytes in NSCLC. Journal of Clinical Oncology. 36: 161-161. DOI: 10.1200/Jco.2018.36.5_Suppl.161  0.479
2018 Chen L, Li Y, Yi X, Gibbons DL. Targeting CD38 to improve anti-PD-1/CTLA-4 combination therapy in lung cancer. Journal of Clinical Oncology. 36: 144-144. DOI: 10.1200/Jco.2018.36.5_Suppl.144  0.406
2018 Reuben A, Gittelman R, Zhang J, Quek K, Vence LM, Behrens C, Chen R, Fujimoto J, Chow C, Wu X, Allison JP, Sharma P, Zhang J, Lee JJ, Sepesi B, ... Gibbons DL, et al. Association of the T-cell receptor landscape with survival in non-small cell lung cancer. Journal of Clinical Oncology. 36: 140-140. DOI: 10.1200/Jco.2018.36.5_Suppl.140  0.479
2018 Tang X, Lu W, Zhang J, Berhens C, Parra ER, Wineman J, Zhang J, Gibbons DL, Koeppel M, Kerns B, Stern M, Sepesi B, Lee JJ, Wistuba II. Abstract 4054: Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC) Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4054  0.459
2018 Parra ER, Jiang M, Zhang J, Behrens C, Lee J, Heymach JV, Forget M, Haymaker C, Bernatchez C, Moran C, Zhang J, Gibbons D, Wistuba I. Abstract 3633: Immunofluorescence profiling of co-expression of multiple immune checkpoints in malignant and tumor infiltrated lymphocytes in non-small cell lung carcinomas using image analysis system Cancer Research. 78: 3633-3633. DOI: 10.1158/1538-7445.Am2018-3633  0.405
2018 Sen T, Chen L, Rodriguez BL, Li L, Li Y, Fan Y, Glisson B, Wang J, Piwnica-Worms H, Sage J, Heymach JV, Gibbons DL, Byers LA. Abstract A108: DNA damage repair targeting upregulates PD-L1 level and potentiates the effect of PD-L1 blockade in small cell lung cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A108  0.432
2018 Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Prado E, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Byers L, Altan M, Elamin Y, ... ... Gibbons D, et al. P1.13-37 Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S596-S597. DOI: 10.1016/J.Jtho.2018.08.894  0.408
2018 Salazar R, Solorzano J, Solis L, Behrens C, Mino B, Parra E, Zhang J, Vaporciyan A, Rice D, Kalhor N, Moran C, Gibbons D, Weissferdt A, Sepesi B, Wistuba I. P1.04-22 CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC) Journal of Thoracic Oncology. 13: S533-S534. DOI: 10.1016/J.Jtho.2018.08.737  0.415
2018 Sepesi B, Federico L, Mitchell K, Parra E, Francisco Cruz A, Ravelli A, Haymaker C, Karpinets T, Cascone T, Weissferdt A, Antonoff M, Walsh G, Bernatchez C, Roth J, Zhang J, ... ... Gibbons D, et al. P1.03-12 PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers Journal of Thoracic Oncology. 13: S516. DOI: 10.1016/J.Jtho.2018.08.693  0.448
2018 Lam V, Tran H, Vasquez M, Li K, Yuen K, Vang F, Jaimovich A, Kennedy D, Odegaard J, Mortimer S, Olsen S, Raymond V, Vaporciyan A, Antonoff M, Walsh G, ... ... Gibbons D, et al. MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer Journal of Thoracic Oncology. 13: S438. DOI: 10.1016/J.Jtho.2018.08.512  0.389
2018 Negrao M, Reuben A, Chen R, Sepesi B, Karpinets T, Parra E, Federico L, Vence L, Weissferdt A, Tran H, Vaporciyan A, Haymaker C, Forget M, Vasquez M, Prado E, ... ... Gibbons D, et al. MA06.02 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON Journal of Thoracic Oncology. 13: S375. DOI: 10.1016/J.Jtho.2018.08.359  0.421
2018 Heymach J, Negrao M, Robichaux J, Carter B, Patel A, Altan M, Gibbons D, Fossella F, Simon G, Lam V, Blumenschein G, Tsao A, Kurie J, Mott F, Jenkins D, et al. OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 13: S323-S324. DOI: 10.1016/J.Jtho.2018.08.243  0.43
2018 Weissferdt A, Cascone T, Pataer A, Kalhor N, Moran C, Antonoff M, Walsh G, Bernatchez C, Gibbons D, Wistuba I, Roth J, Zhang J, Roarty E, Landry L, Vaporciyan A, et al. P3.09-27 Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S958. DOI: 10.1016/J.Jtho.2018.08.1796  0.414
2018 Gomez D, Tang C, Zhang J, Blumenschein G, Hernandez M, Lee J, Ye R, Camidge D, Skoulidis F, Doebele R, Gaspar L, Gibbons D, Karam J, Kavanagh B, Palma D, et al. Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial International Journal of Radiation Oncology*Biology*Physics. 102: 1604. DOI: 10.1016/J.Ijrobp.2018.08.050  0.38
2017 Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 7: e1376156. PMID 29296537 DOI: 10.1080/2162402X.2017.1376156  0.401
2017 Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports. 7: 13380. PMID 29042640 DOI: 10.1038/S41598-017-13942-8  0.344
2017 Wei Y, Kim TJ, Peng DH, Duan D, Gibbons DL, Yamauchi M, Jackson JR, Le Saux CJ, Calhoun C, Peters J, Derynck R, Backes BJ, Chapman HA. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. The Journal of Clinical Investigation. PMID 28872461 DOI: 10.1172/Jci94624  0.348
2017 Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ. Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications. 8: 199. PMID 28775315 DOI: 10.1038/S41467-017-00289-X  0.385
2017 Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, ... ... Gibbons DL, et al. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery. PMID 28733428 DOI: 10.1158/2159-8290.Cd-17-0256  0.394
2017 Sepesi B, Cuentes EP, Canales JR, Behrens C, Correa A, Antonoff M, Gibbons DL, Heymach J, Hofstetter W, Mehran R, Rice DC, Roth J, Vaporciyan AA, Walsh G, Weissferdt A, et al. Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 98: 223. PMID 28586974 DOI: 10.1016/J.Ijrobp.2017.01.060  0.418
2017 Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood A, Fan Y, Li L, Glisson BS, Minna J, Sage J, Gibbons DL, Piwnica-Worms H, Heymach J, et al. CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Cancer Research. PMID 28490518 DOI: 10.1158/0008-5472.Can-16-3409  0.443
2017 Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, et al. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research. PMID 28254787 DOI: 10.1158/2326-6066.Cir-16-0141  0.483
2017 Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, ... ... Gibbons DL, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. PMID 28212573 DOI: 10.18632/Oncotarget.15338  0.438
2017 Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, ... Gibbons DL, et al. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 83-89. PMID 28177435 DOI: 10.1093/Annonc/Mdw437  0.409
2017 Chen L, Byers LA, Ullrich S, Wistuba II, Qin X, Gibbons DL. CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis. Journal of Clinical Oncology. 35: 79-79. DOI: 10.1200/Jco.2017.35.7_Suppl.79  0.43
2017 Seth S, Lee W, Zhang J, Fujimoto J, Behrens C, McDowell C, Kalhor N, Weissferdt A, Papadimitrakopoulou V, Heymach J, Gibbons DL, Futreal A, Wistuba II, Amit M, Kadara H, et al. Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence. Journal of Clinical Oncology. 35: e20058-e20058. DOI: 10.1200/Jco.2017.35.15_Suppl.E20058  0.428
2017 Sepesi B, Lacerda L, Zhang J, Bernatchez C, Karpinets T, Vaporciyan AA, Wistuba II, Roarty E, Heymach J, Gibbons DL. Immunogenomic profiling of non-small cell lung cancer: The ICON project. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20034  0.468
2017 Jalali A, Wang J, Lee W, Zhang J, Wu CC, Gibbons DL, Tang X, Kalhor N, Izzo J, Behrens C, Fossella FV, Tsao AS, Lee JJ, Swisher S, Heymach J, et al. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. Journal of Clinical Oncology. 35: 8538-8538. DOI: 10.1200/Jco.2017.35.15_Suppl.8538  0.413
2017 Sen T, Chen L, Rodriguez BL, Yang Y, Fan YH, Stewart CA, Glisson B, Piwnica-Worms H, Sage J, Heymach JV, Gibbons DL, Byers LA. Abstract B72: Combining immune checkpoint inhibition and DNA damage repair (DDR) targeted therapy in small cell lung cancer (SCLC) Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B72  0.409
2017 Chen L, Diao L, Yang Y, Yi X, Rodriguez J, Fan Y, Rodriguez L, Fradette J, Ungewiss C, Roybal J, Zhu J, Wang J, Byers L, Ullrich S, Wistuba I, ... ... Gibbons D, et al. Abstract 567: CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response Cancer Research. 77: 567-567. DOI: 10.1158/1538-7445.Am2017-567  0.43
2017 Cuentas ER, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Zhang J, Lee J, Heymach J, Moran C, Zhang J, ... Gibbons D, et al. Abstract 2934: Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas Cancer Research. 77: 2934-2934. DOI: 10.1158/1538-7445.Am2017-2934  0.404
2017 Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, ... ... Gibbons D, et al. OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues Journal of Thoracic Oncology. 12: S1780. DOI: 10.1016/J.Jtho.2017.09.404  0.447
2017 Zhang J, Sepesi B, Team II, Gibbons D. P2.02-041 Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project) Journal of Thoracic Oncology. 12: S2114. DOI: 10.1016/J.Jtho.2017.09.1219  0.424
2017 Tang H, Zhang J, Hu X, Xu Y, Dong B, Wang J, Kong Y, Ma H, Liao Z, Zhang J, Byers LA, Gibbons DL, Glisson BS, Wistuba I, Heymach J, et al. P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact Journal of Thoracic Oncology. 12: S710-S711. DOI: 10.1016/J.Jtho.2016.11.936  0.423
2017 Federico L, Haymaker C, Forget M, Vence L, Team I, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons DL, et al. P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S630-S631. DOI: 10.1016/J.Jtho.2016.11.812  0.466
2017 Sepesi B, Team I, Heymach J, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Swisher S, Bernatchez C, Gibbons DL. OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project Journal of Thoracic Oncology. 12: S324-S325. DOI: 10.1016/J.Jtho.2016.11.347  0.431
2017 Parra E, Rodriguez-Canales J, Behrens C, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, William W, Lee J, Heymach J, Moran C, Zhang J, ... Gibbons DL, et al. OA20.05 The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas Journal of Thoracic Oncology. 12: S323-S324. DOI: 10.1016/J.Jtho.2016.11.346  0.407
2017 Behrens C, Parra E, Rodriguez-Canales J, Villalobos P, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Moran C, Gibbons D, Wistuba I. OA19.02 Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma Journal of Thoracic Oncology. 12: S318. DOI: 10.1016/J.Jtho.2016.11.338  0.409
2017 Tran H, Zhang J, Vasquez M, Fossella F, Simon G, Tsao A, Gibbons DL, Elamin Y, Banks K, Lanman R, Papadimitrakopoulou V, Heymach J. P2.03b-030 Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer Journal of Thoracic Oncology. 12: S952. DOI: 10.1016/J.Jtho.2016.11.1311  0.372
2017 Parra E, Villalobos P, Zhang J, Behrens C, Mino B, Moran C, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Lee J, Zhang J, Gibbons DL, Rodrigues-Canales J, et al. P2.01-061 Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas Journal of Thoracic Oncology. 12: S823-S824. DOI: 10.1016/J.Jtho.2016.11.1113  0.388
2017 Roszik J, Gibbons DL, Heymach J, Vaporciyan A, Swisher S, Sepesi B. P2.01-054 Lung Cancer PD-L1 mRNA Expression Profile and Clinical Outcomes - An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia Journal of Thoracic Oncology. 12: S818-S819. DOI: 10.1016/J.Jtho.2016.11.1106  0.417
2016 Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, ... Gibbons DL, et al. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology. 5: e1234570. PMID 27999749 DOI: 10.1080/2162402X.2016.1234570  0.454
2016 Tan X, Banerjee P, Guo HF, Ireland S, Pankova D, Ahn YH, Nikolaidis IM, Liu X, Zhao Y, Xue Y, Burns AR, Roybal J, Gibbons DL, Zal T, Creighton CJ, et al. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. The Journal of Clinical Investigation. PMID 27869652 DOI: 10.1172/Jci88736  0.38
2016 Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The Lancet. Oncology. PMID 27789196 DOI: 10.1016/S1470-2045(16)30532-0  0.384
2016 Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie JM, Gibbons DL, Mills GB, Wistuba II, Creighton CJ. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. PMID 27775076 DOI: 10.1038/Onc.2016.303  0.431
2016 Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, ... ... Gibbons DL, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene. PMID 27694892 DOI: 10.1038/Onc.2016.358  0.454
2016 Kadara H, Choi M, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, ... Gibbons DL, et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27687306 DOI: 10.1093/Annonc/Mdw436  0.392
2016 Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, et al. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27480147 DOI: 10.1200/Jco.2015.66.0084  0.447
2016 Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y. A genetic cell context-dependent role for ZEB1 in lung cancer. Nature Communications. 7: 12231. PMID 27456471 DOI: 10.1038/Ncomms12231  0.423
2016 Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, ... ... Gibbons DL, et al. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America. PMID 27274057 DOI: 10.1073/Pnas.1513616113  0.475
2016 Parra ER, Behrens C, Rodriguez-Canales J, Lin HY, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, et al. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252415 DOI: 10.1158/1078-0432.Ccr-15-2443  0.443
2016 Gibbons DL, Chow LQ, Kim DW, Kim SW, Yeh T, Song X, Jiang H, Taylor R, Karakunnel J, Creelan B. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S79. PMID 27198414 DOI: 10.1016/S1556-0864(16)30171-X  0.312
2016 Albritton JL, Roybal JD, Paulsen SJ, Calafat N, Flores-Zaher JA, Farach-Carson MC, Gibbons DL, Miller JS. Ultrahigh-throughput Generation and Characterization of Cellular Aggregates in Laser-ablated Microwells of Poly(dimethylsiloxane). Rsc Advances. 6: 8980-8991. PMID 26998251 DOI: 10.1039/C5Ra26022A  0.301
2016 Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Wistuba II, Hwu P, Heymach JV, Gibbons DL, Rodriguez J. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26851185 DOI: 10.1158/1078-0432.Ccr-15-1434  0.393
2016 Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Scientific Reports. 6: 18652. PMID 26728244 DOI: 10.1038/Srep18652  0.398
2016 Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach J. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: e23064-e23064. DOI: 10.1200/Jco.2016.34.15_Suppl.E23064  0.408
2016 Tang H, Zhang J, Hu X, Xu Y, Dong B, Kong Y, Zhang X, Liao ZX, Zhang J, Byers LA, Gibbons DL, Glisson BS, Wistuba II, Heymach J, Gomez DR, et al. Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations. Journal of Clinical Oncology. 34: e20089-e20089. DOI: 10.1200/Jco.2016.34.15_Suppl.E20089  0.432
2016 Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Camidge DR, Doebele RC, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Komaki R, Louie AV, Palma DA, Tsao AS, William WN, et al. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. Journal of Clinical Oncology. 34: 9004-9004. DOI: 10.1200/Jco.2016.34.15_Suppl.9004  0.384
2016 Zhang J, Fujimoto J, Yusko E, Zhang J, Vignali M, Song X, Rodriguez-Canales J, Parra Cuentas ER, Behrens C, Benzeno S, Robins H, Gibbons DL, Swisher S, Heymach J, Futreal A, et al. Intra-tumor heterogeneity of T cell receptor repertoire in lung cancers and its association with tumor genomic profile. Journal of Clinical Oncology. 34: 8539-8539. DOI: 10.1200/Jco.2016.34.15_Suppl.8539  0.479
2016 Chen L, Lou Y, Wistuba I, Ullrich S, Qin X, Byers L, Heymach J, Gibbons D. Abstract A086: EMT produces an immunosuppressive tumor microenvironment Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A086  0.475
2016 Sen T, Tong P, Stewart CA, Cristea S, Hong-Fan Y, Glisson BS, Gibbons DL, Sage J, Wang J, Byers LA. Abstract PR10: Exploiting the G2-M cell cycle checkpoint dependency in small cell lung cancer (SCLC) using pharmacological inhibitors of CHK1 and WEE1 Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-Pr10  0.45
2016 Chen L, Lou Y, Heymach J, Wistuba I, Ullrich S, Qin X, Gibbons D. Abstract PR01: Targeting the EMT-immunosuppression loop in lung cancer as a strategy to prevent metastasis Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-Pr01  0.474
2016 Kundu ST, Grzeskowiak C, Creighton CJ, Scott KL, Gibbons DL. Abstract B25: A novel in vivo gain-of-function screen for metastasis drivers in non-small cell lung cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-B25  0.472
2016 Peng DH, Tong P, Byers LA, Wang J, Creighton CJ, Gibbons DL. Abstract A27: Zeb1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-A27  0.474
2016 Kundu S, Diao L, Glisson BS, Wang J, Heymach JV, Byers LA, Gibbons DL. Abstract LB-170: Unique microRNA signatures in small cell lung cancer correlate with distinct protein expression profiles and drug response Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-170  0.38
2016 Kadara H, Choi M, Zhang J, Cuentas EP, Canales JR, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher SG, Gibbons DL, et al. Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma Cancer Research. 76: 89-89. DOI: 10.1158/1538-7445.Am2016-89  0.429
2016 Kundu S, Grzeskowiak C, Creighton CJ, Scott KL, Gibbons DL. Abstract 688: Identifying TMEM106B as a novel metastasis driver in non-small cell lung cancers through anin vivogain-of-function screen Cancer Research. 76: 688-688. DOI: 10.1158/1538-7445.Am2016-688  0.47
2016 Denning WL, Skoulidis F, Shen L, Papadimitrakopoulou V, Diao L, Lou Y, Byers LA, Wang J, Canales JR, Wistuba II, Weinstein J, Gibbons DL, Heymach JV. Abstract 4137: Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma Cancer Research. 76: 4137-4137. DOI: 10.1158/1538-7445.Am2016-4137  0.429
2016 Kudinov A, Deneka A, Nikonova A, Serebriiskii I, Beck TN, Cai Q, Egleston BL, Nicolas E, Borghaei H, Gibbons D, Kurie J, Golemis EA, Boumber Y. Abstract 1584: Musashi-2 (MSI2) drives TGFBR1/SMAD3 dependent partial EMT and supports VEGFR2 expression and metastasis of human and mouse NSCLC cells Cancer Research. 76: 1584-1584. DOI: 10.1158/1538-7445.Am2016-1584  0.465
2016 Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, et al. Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma Cancer Research. 76: 142-142. DOI: 10.1158/1538-7445.Am2016-142  0.425
2015 Pankoval D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, ... ... Gibbons DL, et al. Cancer-associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Molecular Cancer Research : McR. PMID 26631572 DOI: 10.1158/1541-7786.Mcr-15-0307  0.422
2015 Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna JD, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, et al. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26597303 DOI: 10.1158/1078-0432.Ccr-14-2890  0.35
2015 Mak M, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26420858 DOI: 10.1158/1078-0432.Ccr-15-0876  0.438
2015 Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology. 4: e1002731. PMID 26155392 DOI: 10.1080/2162402X.2014.1002731  0.365
2015 Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene. PMID 25798833 DOI: 10.1038/Onc.2015.71  0.395
2015 Mak MP, Diao L, Tong P, Wang J, Ng PKS, Cardnell R, Hayes DN, Robertson G, Myers J, El-Naggar AK, William WN, Coombes KR, Weinstein JN, Mills GB, Heymach J, ... Gibbons DL, et al. Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers. Journal of Clinical Oncology. 33: 6016-6016. DOI: 10.1200/Jco.2015.33.15_Suppl.6016  0.445
2015 Creelan BC, Chow LQ, Kim D, Kim S, Yeh T, Karakunnel JJ, Gibbons DL. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 3047-3047. DOI: 10.1200/Jco.2015.33.15_Suppl.3047  0.36
2015 Lou Y, Diao L, Parra Cuentas ER, Denning W, Chen L, Fan YH, Rodriguez J, Byers LA, Wang J, Papadimitrakopoulou V, Behrens C, Wistuba II, Hwu P, Heymach J, Gibbons DL. Association of epithelial-mesenchymal transition with an immunosuppressive, inflammatory tumor microenvironment with elevated levels of checkpoint inhibitors in lung adenocarcinoma. Journal of Clinical Oncology. 33: 3030-3030. DOI: 10.1200/Jco.2015.33.15_Suppl.3030  0.47
2015 Skoulidis F, Denning W, Diao L, Tong P, Fan YH, Papadimitrakopoulou V, Izzo J, Behrens C, Kadara H, Parra Cuentas ER, Rodriguez J, Wang J, Gibbons DL, Byers LA, Wistuba II, et al. Association of inactivation of STK11/ LKB1 with a suppressive immune microenvironment in lung adenocarcinoma (LUAC). Journal of Clinical Oncology. 33: 11002-11002. DOI: 10.1200/Jco.2015.33.15_Suppl.11002  0.367
2015 Chen L, Goswami S, Yi X, Byers L, Diao L, Roybal J, Ungewiss C, Peng D, Wang J, Wistuba I, Chen L, Ullrich S, Heymach J, Kurie J, Qin X, ... Gibbons D, et al. Abstract B67: A big role in tumor immune microenvironment of a small non-coding RNA: microRNA-200 Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B67  0.476
2015 Ungewiss C, Roybal JD, Peng DH, Gibbons DL. Abstract B44: The microRNA-200/Zeb1 axis regulates ECM-dependent Src signaling, cytoskeletal changes and cancer cell invasion Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B44  0.367
2015 Grzeskowiak CL, Minelli R, Wu P, Kundu S, Gibbons DL, Scott KL. Abstract 955: High-throughput functional screening for metastasis drivers of lung cancer Cancer Research. 75: 955-955. DOI: 10.1158/1538-7445.Am2015-955  0.458
2015 Valliani AA, Sen T, Masrorpour F, Diao L, Cardnell RJ, Wang J, Glisson BS, Piwnica-Worms H, Gibbons DL, Byers LA. Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC) Cancer Research. 75: 5316-5316. DOI: 10.1158/1538-7445.Am2015-5316  0.448
2015 Denning WL, Diao L, Skoulidis F, Lou Y, Byers L, Wang J, Weinstein J, Gibbons D, Heymach J. Abstract 456: Defined co-mutation subgroups of KRAS-mutated NSCLC display distinct immune profiles Cancer Research. 75: 456-456. DOI: 10.1158/1538-7445.Am2015-456  0.447
2015 Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Lou Y, Gibbons DL, Heymach JV, Swisher SG, Weissferdt A, Kahlor N, Izzo J, Lee JJ, Kadara H, et al. Abstract 4256: High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma Cancer Research. 75: 4256-4256. DOI: 10.1158/1538-7445.Am2015-4256  0.452
2015 Kudinov A, Deneka AD, Nikonova A, Ahn Y, Liu XL, Serebriiskii I, Efimov A, Yang D, Andrake MA, Nicolas E, Egleston B, Borghaei H, Gibbons D, Kurie J, Golemis E, et al. Abstract 4098: Musashi-2 (MSI2) activates TGF-β signaling and inhibits CLDN7 to promote non-small cell lung cancer (NSCLC) metastasis Cancer Research. 75: 4098-4098. DOI: 10.1158/1538-7445.Am2015-4098  0.483
2015 Lou Y, Diao L, Roger PCE, Denning WL, Chen L, Fan Y, Rodriguez J, Byers L, Wang J, Papadimitrakopoulou V, Carmen B, Wistuba II, Hwu P, Heymach JV, Gibbons DL. Abstract 3364: Epithelial-mesenchymal transition is associated with a profound inflammatory tumor microenvironment in lung adenocarcinoma Cancer Research. 75: 3364-3364. DOI: 10.1158/1538-7445.Am2015-3364  0.477
2014 Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications. 5: 5241. PMID 25348003 DOI: 10.1038/Ncomms6241  0.398
2014 Gibbons DL, Byers LA. A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discovery. 4: 991-4. PMID 25185188 DOI: 10.1158/2159-8290.Cd-14-0791  0.38
2014 Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. The Journal of Clinical Investigation. 124: 2696-708. PMID 24762440 DOI: 10.1172/Jci72171  0.461
2014 Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Molecular Cancer Research : McR. 12: 3-13. PMID 24442106 DOI: 10.1158/1541-7786.Mcr-13-0539  0.386
2014 Mishra DK, Creighton CJ, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. International Journal of Cancer. Journal International Du Cancer. 134: 789-98. PMID 23934967 DOI: 10.1002/Ijc.28428  0.394
2014 Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn Y, Byers LA, Lin W, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, et al. Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis. Journal of Clinical Oncology. 32: 8063-8063. DOI: 10.1200/Jco.2014.32.15_Suppl.8063  0.443
2014 Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach J. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. Journal of Clinical Oncology. 32: 3018-3018. DOI: 10.1200/Jco.2014.32.15_Suppl.3018  0.472
2014 Xia D, Byers LA, Diao L, Wang J, Lin SH, Gibbons DL, Gold KA, Paul J, Liu N, Heymach JV. Abstract 3702: Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Cancer Research. 74: 3702-3702. DOI: 10.1158/1538-7445.Am2014-3702  0.402
2014 Gibbons DL, Chen L, Goswami S, Ahn Y, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba I, et al. Abstract A21: microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis. Clinical Cancer Research. 20: A21-A21. DOI: 10.1158/1078-0432.14Aacriaslc-A21  0.452
2014 Mak M, Tong P, Diao L, Ng P, Fan Y, Cardnell R, Gibbons D, William W, Heymach J, Coombes K, Byers L, Wang J. 435 A pan-cancer tumor-derived epithelial-to–mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT European Journal of Cancer. 50: 143. DOI: 10.1016/S0959-8049(14)70561-1  0.368
2014 Kim M, Mishra D, Thrall M, Creighton C, Gibbons D, Kurie J, Kim M. A549 and H1299 Cells Form Metastatic Lesions in the Ex Vivo 4D Lung Cancer Model Journal of Surgical Research. 186: 557-558. DOI: 10.1016/J.Jss.2013.11.469  0.361
2013 Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Management and Research. 5: 187-95. PMID 23986650 DOI: 10.2147/Cmar.S35171  0.418
2013 Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, ... ... Gibbons DL, et al. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. Plos One. 8: e67054. PMID 23785517 DOI: 10.1371/Journal.Pone.0067054  0.408
2013 Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, ... ... Gibbons DL, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery. 3: 870-9. PMID 23715154 DOI: 10.1158/2159-8290.Cd-13-0015  0.473
2013 Gold KA, Byers LA, Fan YH, Fujimoto J, Tse WH, Lee JJ, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8104-8104. DOI: 10.1200/Jco.2013.31.15_Suppl.8104  0.348
2013 Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Talpaz M, Cortes JE, Donato NJ, Quintas-Cardama A. Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia Blood. 122: 853-853. DOI: 10.1182/Blood.V122.21.853.853  0.31
2013 Roybal JD, Peng DH, Ungewiss C, Mandal PK, McMurray JS, Byers LA, Gibbons DL. Abstract C57: The role of the microRNA-200 family in the regulation of tumor cell signaling and metastasis in lung cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C57  0.47
2013 Ungewiss C, Roybal JD, Peng DH, Gibbons DL. Abstract C56: microRNA-200 control of tumor cell cytoskeletal changes and invasion Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C56  0.416
2013 Boumber Y, Kudinov A, Liu X, Ahn Y, Rodriguez J, Wistuba I, Gibbons D, Kurie J. Abstract 2690: The role of musashi-1 in tumor progression in non-small cell lung cancer. Cancer Research. 73: 2690-2690. DOI: 10.1158/1538-7445.Am2013-2690  0.494
2013 Mishra DK, Creighton C, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Abstract 1508: Gene expression analysis of perfusable nodules grown onex vivo3D model shows effects on extracellular matrix, cell signaling and immune response. Cancer Research. 73: 1508-1508. DOI: 10.1158/1538-7445.Am2013-1508  0.376
2013 Pricl S, Gibbons DL, Posocco P, Laurini E, Giabbai B, Storici P, Fermeglia M, Sun H, Cortes J, Talpaz M, Donato N, Quintas-Cardama A. Abstract B277: Polymutant BCR-ABL1 proteins during chronic myeloid leukemia therapy: Novel mechanisms of resitance from clinical, in vitro, and in silico evidence. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B277  0.331
2012 Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, West JL. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Research. 72: 6013-23. PMID 22952217 DOI: 10.1158/0008-5472.Can-12-0895  0.354
2012 Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. The Journal of Clinical Investigation. 122: 3170-83. PMID 22850877 DOI: 10.1172/Jci63608  0.357
2012 Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie J, Ohashi P, Muthuswamy SK. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. Plos One. 7: e34343. PMID 22529912 DOI: 10.1371/Journal.Pone.0034343  0.31
2012 Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintás-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 118: 293-9. PMID 21732333 DOI: 10.1002/Cncr.26225  0.328
2012 Mishra DK, Baird BN, Ott HC, Gibbons DL, Kurie JM, Kim MP. Abstract 345: Circulating tumor cells from perfusable tumor nodules grown on decellularized rat lung scaffold has mesenchymal characteristics Cancer Research. 72: 345-345. DOI: 10.1158/1538-7445.Am2012-345  0.434
2011 Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Research. 71: 7670-82. PMID 21987723 DOI: 10.1158/0008-5472.Can-11-0964  0.397
2011 Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Molecular and Cellular Biology. 31: 4270-85. PMID 21896780 DOI: 10.1128/Mcb.05562-11  0.457
2011 Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. The Journal of Clinical Investigation. 121: 1373-85. PMID 21403400 DOI: 10.1172/Jci42579  0.384
2011 Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. The New England Journal of Medicine. 364: 947-55. PMID 21388312 DOI: 10.1056/Nejmct0807960  0.444
2011 Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Molecular Cancer Research : McR. 9: 25-35. PMID 21115742 DOI: 10.1158/1541-7786.Mcr-10-0497  0.421
2009 Gibbons DL, Lin W, Creighton C, Zhang S, Lozano G, Kurie J. Use of a murine model of NSCLC to evaluate the role of the microRNA-200 family in regulating EMT and metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11006. PMID 27964037 DOI: 10.1200/Jco.2009.27.15_Suppl.11006  0.451
2009 Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes & Development. 23: 2140-51. PMID 19759262 DOI: 10.1101/Gad.1820209  0.384
2009 Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. Plos One. 4: e5401. PMID 19404390 DOI: 10.1371/Journal.Pone.0005401  0.463
2009 Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. The Journal of Biological Chemistry. 284: 17766-74. PMID 19398556 DOI: 10.1074/Jbc.M109.003111  0.378
2009 Yang Y, Ahn Y, Gibbons DL, Zang Y, Lin W, Thilaganthan N, Moreira DC, Creighton CJ, Goodall GJ, Kurie JM. Abstract A29: The Notch ligand Jagged2 promotes metastasis through a GATA3/miR‐200 regulatory loop Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A29  0.376
2007 Quintás-Cardama A, Gibbons DL. Five-gene signature in non-small-cell lung cancer. The New England Journal of Medicine. 356: 1582-3; author reply. PMID 17436429  0.331
2004 Gibbons DL, Reilly B, Ahn A, Vaney MC, Vigouroux A, Rey FA, Kielian M. Purification and crystallization reveal two types of interactions of the fusion protein homotrimer of Semliki Forest virus. Journal of Virology. 78: 3514-23. PMID 15016874 DOI: 10.1128/Jvi.78.7.3514-3523.2004  0.576
2004 Gibbons DL, Ahn A, Liao M, Hammar L, Cheng RH, Kielian M. Multistep regulation of membrane insertion of the fusion peptide of Semliki Forest virus. Journal of Virology. 78: 3312-8. PMID 15016852 DOI: 10.1128/Jvi.78.7.3312-3318.2004  0.668
2004 Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, Lepault J, Kielian M, Rey FA. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature. 427: 320-5. PMID 14737160 DOI: 10.1038/Nature02239  0.576
2003 Gibbons DL, Erk I, Reilly B, Navaza J, Kielian M, Rey FA, Lepault J. Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography. Cell. 114: 573-83. PMID 13678581 DOI: 10.1016/S0092-8674(03)00683-4  0.574
2002 Ahn A, Gibbons DL, Kielian M. The fusion peptide of Semliki Forest virus associates with sterol-rich membrane domains. Journal of Virology. 76: 3267-75. PMID 11884551 DOI: 10.1128/Jvi.76.7.3267-3275.2002  0.574
2002 Gibbons DL, Kielian M. Molecular dissection of the Semliki Forest virus homotrimer reveals two functionally distinct regions of the fusion protein. Journal of Virology. 76: 1194-205. PMID 11773395 DOI: 10.1128/Jvi.76.3.1194-1205.2002  0.581
2000 Gibbons DL, Ahn A, Chatterjee PK, Kielian M. Formation and characterization of the trimeric form of the fusion protein of Semliki Forest virus Journal of Virology. 74: 7772-7780. PMID 10933683 DOI: 10.1128/Jvi.74.17.7772-7780.2000  0.578
2000 Kielian M, Chatterjee PK, Gibbons DL, Lu YE. Specific roles for lipids in virus fusion and exit. Examples from the alphaviruses Sub-Cellular Biochemistry. 34: 409-455. PMID 10808340 DOI: 10.1007/0-306-46824-7_11  0.674
Show low-probability matches.